Despite advances in the treatment of pediatric cancer patients, outcomes for high-risk and relapsed tumors remain disappointing and are often associated with serious side effects. This study analysed the genomic and transcriptomic profiles of 230 pediatric patients with malignant solid tumors and 18 patients with recurrent or otherwise difficult-to-treat nonmalignant conditions. Clinically significant genetic alterations were found in 55% of the patients' tumors, and individualised treatment strategies were suggested based on molecular findings in 38%. The study highlights the contribution of precision oncology in optimising treatment and refining diagnosis in pediatric oncology.
More information on the contents of the publication can be found at the following link: Real-World Performance of Integrative Clinical Genomics in Pediatric Precision Oncology - Laboratory Investigation.